Selective inhibitors of the Aurora A-TPX2 protein-protein interaction exhibit in vivo efficacy as targeted anti-mitotic agents
Stockwell, S. R.; Scott, D. E.; Fischer, G.; Guarino, E.; Rooney, T. P. C.; Fang, T.-S.; Moschetti, T.; Srinivasan, R.; Alza, E.; Asteian, A.; Dagostin, C.; Alcaide, A.; Rocaboy, M.; Blaszczyk, B.; Higueruelo, A.; Wang, X.; Rossmann, M.; Perrior, T. R.; Blundell, T. L.; Spring, D. R.; McKenzie, G.; Abell, C.; Skidmore, J.; Hyvönen, M.; Venkitaraman, A. R.
Show abstract
The protein kinase Aurora A, and its close relative, Aurora B, regulate human cell division. Aurora A is frequently overexpressed in cancers of the breast, ovary, pancreas and blood, provoking genome instability and resistance to anti-mitotic chemotherapy. Intracellular localization and enzymatic activity of Aurora A are regulated by its interaction with the spindle assembly factor TPX2. Here, we have used fragment-based, structure-guided lead discovery to develop small-molecule inhibitors of the Aurora A-TPX2 protein-protein interaction (PPI). These compounds act by novel mechanism compared to existing Aurora A inhibitors and they are highly specific to Aurora A over Aurora B. Our biophysically, structurally and phenotypically validated lead compound, CAM2602, exhibits oral bioavailability, favourable pharmacokinetics, pharmacodynamic biomarker modulation, and arrest of growth in tumour xenografts. Consistent with our original finding that Aurora A overexpression drives taxane-resistance in cancer cells, inhibition of Aurora A-TPX2 PPI synergizes with paclitaxel to suppress the outgrowth of pancreatic cancer cells. Our results provide a blueprint for targeting the Aurora A-TPX2 PPI for cancer therapy and suggest a promising clinical utility for this mode of action.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Structure-Based Virtual Screening Identifies TREM2-Targeted Small Molecules that Enhance Microglial Phagocytosis 94%
- A novel inhibitor against the bromodomain PfBDP1 of the malaria pathogen Plasmodium falciparum 93%
- Structure-Activity Relationships, Tolerability and Efficacy of Microtubule-Active 1,2,4-Triazolopyrimidines as Potential Candidates to Treat Human African Trypanosomiasis 92%
Similar papers in this journal
Similar papers in this journal
- Characterisation of RNA guanine-7 methyltransferase (RNMT) using a small molecule approach 93%
- Development of novel anti-malarial from structurally diverse library of molecules, targeting plant-like Calcium Dependent Protein Kinase 1, a multistage growth regulator of P. falciparum 92%
- Artemether and Euphorbia Factor L9 suppress kynurenine production through distinct effects on Tryptophan metabolism. 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.